Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Name: Kaimen Rigor review — Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.
Item: Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.
Rating: 100
Author: Alpha1

Proud CM, Vũ DC, Wilmshurst JM, Sanmaneechai O, Gulati S, Xiong H, Moreno HC, Tay SKH, Thong MK, Born AP, Banzzatto Ortega A, Jong YJ, Al-Muhaizea MA, Lee AW, Visootsak J, Tauscher-Wisniewski S, Alecu I, Parlikar R, Finkel RS, STEER Study Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 0 high issues for “Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04103-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e32281f8-46c9-4a37-8c4c-ffb114eafb82" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e32281f8-46c9-4a37-8c4c-ffb114eafb82/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 0 high issues for “Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0c49c82270faaa39c97fc72936fbc09e6010f6a132dfa25ff03ce1e8e35ff781

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Paper source

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is the change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) score, which is a functional motor scale, not a hard clinical outcome. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking HFMSE changes to long-term clinical outcomes such as survival or need for ventilation. The claim of clinical benefit is based on a surrogate motor function scale.
“Primary efficacy endpoint was change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) score.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect size is a least squares mean difference of 1.88 points on the HFMSE scale (0-66 points), which is a small fraction of the scale range. The paper mentions a 3-point threshold for responder analysis and a 1.5-point minimal clinically important difference, but the observed difference of 1.88 is below the 3-point threshold and only slightly above the 1.5-point MCID. The clinical meaningfulness is not robustly established, especially given the small magnitude relative to the scale.
“least squares mean difference, 1.88 (95% confidence interval: 0.51−3.25); P = 0.0074”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted Phase 3 randomized, sham-controlled, double-blind trial with rigorous design, thorough ethical documentation, and transparent reporting. Minor reporting gaps include lack of explicit statistical software identification and explicit reporting guideline statement, but these do not undermine the overall robustness.

Both reviewers independently scored all dimensions as pass with high confidence, and their evidence was consistent. The statistics verification checked 5 tests, all consistent; citation check found no retracted or missing references; integrity check found only low-severity internal consistency observations that were resolved as expected. The paper is a clinical trial, so many sub-criteria (e.g., animal housing, cell line authentication) are not applicable.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 3 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on SMA treatments and the STRONG trial, acknowledges the limitations of existing therapies, and justifies the need for a one-time gene therapy. The rationale links the unmet need to the study objectives and hypothesis.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

“In a completed phase 1/2 dose-ranging trial (STRONG; NCT03381729), OAV101 IT was demonstrated to be safe and well tolerated in patients with SMA aged 6 months to <60 months.”

“As such, there remains a need for a safe and effective, one-time gene therapy option that provides sustained expression of SMN protein.”

Introduction ¶2Find in source

“Challenges associated with chronic administration include the burden of repeated administration and potential non-compliance.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

“In a completed phase 1/2 dose-ranging trial (STRONG; NCT03381729), OAV101 IT was demonstrated to be safe and well tolerated in patients with SMA aged 6 months to <60 months.”

“As such, there remains a need for a safe and effective, one-time gene therapy option that provides sustained expression of SMN protein.”

Introduction ¶2Find in source

“Challenges associated with chronic administration include the burden of repeated administration and potential non-compliance.”

Introduction ¶2Find in source

Randomization was stratified by age and baseline HFMSE score, with a 3:2 allocation. Blinding of participants, caregivers, evaluators, and investigators is described. The sample size was pre-specified (125 participants). Inclusion/exclusion criteria are detailed. The analysis population and missing-data approach are defined.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with randomization, blinding, and a pre-specified analysis plan.

Evidence

“Randomization was stratified by age and the highest pretreatment HFMSE score at screening as follows to ensure that both OAV101 IT and sham groups were balanced in terms of baseline characteristics of age and motor function: age 2 to <5 years, HFMSE score ≤15 or >15; age 5 to <13 years, HFMSE score ≤10 or >10; age 13 to <18 years, no stratification based on HFMSE score.”

MethodsFind in source

“Participants (and their caregivers), clinical evaluators who performed the HFMSE and the RULM assessments and study investigators were blinded.”

MethodsFind in source

“The STEER study aimed to enroll 125 participants to receive OAV101 IT ( n ≈ 75) or sham procedure ( n ≈ 50).”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, and prespecified analysis.

Evidence

MethodsFind in source

“Participants (and their caregivers), clinical evaluators who performed the HFMSE and the RULM assessments and study investigators were blinded.”

MethodsFind in source

“The STEER study aimed to enroll 125 participants to receive OAV101 IT ( n ≈ 75) or sham procedure ( n ≈ 50).”

MethodsFind in source

The paper reports age, sex, SMN2 copy number, and baseline motor function scores. Since both sexes are enrolled, sex justification is not applicable. Age and health status are reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographics and baseline characteristics are well reported, including age, sex, and SMN2 copy number.

Evidence

“Male | 34 (45.3) | 28 (54.9) | 62 (49.2)”

Table 1Find in source

“Mean (s.d.) age at dosing was 5.89 (3.58; range, 2.1–16.6) years for the OAV101 IT group and 5.87 (3.05; range, 2.4–14.2) years for the sham group.”

ResultsFind in source

paraphrase[Table 1]

“SMN2 copy number, n (%) | 2 | 1 (1.3) | 4 (7.8) | 5 (4.0)”

PASSReviewer 2· 90% conf

Demographic and baseline characteristics are well reported, including age, sex, and SMN2 copy number.

Evidence

“Male | 34 (45.3) | 28 (54.9) | 62 (49.2)”

Table 1Find in source

“Mean (s.d.) age at dosing was 5.89 (3.58; range, 2.1–16.6) years for the OAV101 IT group and 5.87 (3.05; range, 2.4–14.2) years for the sham group.”

ResultsFind in source

paraphrase[Table 1]

“SMN2 copy number, n (%) | 2 | 1 (1.3) | 4 (7.8) | 5 (4.0)”

The methods list numerous named IRBs that approved the study, and written informed consent from parents/guardians is stated. Compliance with ICH-GCP and Declaration of Helsinki is declared.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals from named IRBs and informed consent are documented.

Evidence

paraphrase[Methods, Ethics]

“The study was approved by institutional review boards (IRBs) at all participating institutions (Institute Ethics Committee at Sir Ganga Ram Hospital, New Delhi, India, and P.D. Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; ...)”

“Written informed consent was obtained from parents or legal guardians (and assent as appropriate) before participation.”

MethodsFind in source

“STEER was undertaken in accordance with the International Council for Harmonisation E6 Guidelines for Good Clinical Practice with the ethical principles in accordance with the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and informed consent are thoroughly documented.

Evidence

paraphrase[Methods, Ethics]

“Written informed consent was obtained from parents or legal guardians (and assent as appropriate) before participation.”

MethodsFind in source

The drug is named, with dose (1.2 × 10^14 vector genomes) and route (intrathecal). The sham procedure is described. No other key biological/chemical resources are used, so other sub-criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (OAV101 IT) is identified with dose and administration details.

Evidence

“OAV101 IT was delivered as a single IT injection under sedation/anesthesia.”

MethodsFind in source

“evaluating the efficacy and safety of OAV101 IT (1.2 × 10 14 vector genomes)”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product is adequately identified, and statistical software is mentioned.

Evidence

“OAV101 IT delivers the SMN transgene via an AAV9 vector and is identical to that used in the STRONG study and the current intravenous formulation.”

MethodsFind in source

“OAV101 IT (1.2 × 10 14 vector genomes)”

MethodsFind in source

absence[Methods, Data analysis]

Statistical software is not explicitly named.

The primary analysis uses a mixed model with repeated measurements, and the paper reports LSM differences with 95% CIs and p-values. Secondary endpoints are reported with nominal p-values. The paper reports by estimation with CIs, so exact p-values are not required for all endpoints. Software is not explicitly named, but the analysis is standard.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported.

Evidence

“The primary efficacy endpoint was analyzed using a mixed model with repeated measurements, with the observed change from baseline in HFMSE score at all post-baseline visits (through the end of Follow-Up Period 1) as the dependent variable.”

Figure 2Find in source

“least squares mean difference, 1.88 (95% confidence interval: 0.51−3.25); P = 0.0074”

ResultsFind in source

absence[Methods, Data analysis]

Statistical software is not identified.

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals.

Evidence

Figure 2Find in source

paraphrase[Results, Primary efficacy endpoint]

“P = 0.0074”

“least squares mean difference, 1.88 (95% confidence interval: 0.51−3.25)”

ResultsFind in source

The data availability statement names a managed-access platform (ClinicalStudyDataRequest) with conditions for access. Since patient-level data are identifiable, repository deposit and accession numbers are not applicable. No bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement provides a concrete access route via ClinicalStudyDataRequest.

Evidence

paraphrase[Data availability]

“This trial data availability is according to the criteria and process described at https://www.clinicalstudydatarequest.com/.”

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route.

Evidence

“Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit.”

Data availabilityFind in source

“This trial data availability is according to the criteria and process described at https://www.clinicalstudydatarequest.com/”

Data availabilityFind in source

The trial is registered (NCT05089656). Limitations are discussed. Conclusions are proportional. Funding and competing interests are disclosed. A reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration: ClinicalTrials.gov identifier: NCT05089656”

AbstractFind in source

“Possible limitations of this study include broad inclusion of all patients regardless of baseline HFMSE and wide age range in the eligibility criteria.”

Discussion ¶7Find in source

“Novartis Pharma AG sponsored this clinical trial.”

Competing interestsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with trial registration, limitations, and funding disclosures.

Evidence

“Trial registration: ClinicalTrials.gov identifier: NCT05089656”

AbstractFind in source

“Possible limitations of this study include broad inclusion of all patients regardless of baseline HFMSE and wide age range in the eligibility criteria.”

DiscussionFind in source

“This study was supported by Novartis Pharma AG, which was involved in the study design, data collection, data analysis, data interpretation and writing of all related reports and publications.”

AcknowledgementsFind in source

Registered (3 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 27 references by DOI: 22 verified — 5 no DOI (shown, not verified).

1 data/code link found; not probed for liveness in this run.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (statistical software not named, reporting guideline not explicitly stated) as non-substantive. No erratum or re-analysis is warranted based on the evidence reviewed.

1.
MEDIUMstatistics
In the Methods, Data analysis section, explicitly name the statistical software (e.g., SAS version) used for all analyses.
Naming the software enhances reproducibility and is a standard expectation for clinical trial reporting.
2.
MEDIUMreporting
In the Methods or Reporting Summary, state explicit adherence to CONSORT guidelines and provide the checklist.
Explicitly citing the reporting guideline improves transparency and aligns with journal requirements.
3.
MEDIUMreporting
In the Methods, Data analysis section, specify the software used for the mixed model and logistic regression analyses.
Clarifying the software for specific analyses aids reproducibility.
4.
MEDIUMdata code
In the Data availability section, clarify the timeframe for data access requests.
Providing a timeline helps readers understand when data will be available.
5.
MEDIUMreporting
In the Discussion, add a sentence on the generalizability of the results to broader SMA populations.
Addressing generalizability strengthens the interpretation of the findings.
6.
LOWcopyedit
In the Author list, separate author names with commas and ensure correct formatting (e.g., 'Vũ Dũng Chí Wilmshurst Jo M.').
Correct author formatting is essential for indexing and professional presentation.
7.
LOWcopyedit
In the Abstract, standardize the formatting of confidence intervals (e.g., use en dash consistently) and terminology ('least squares mean difference' vs 'LSM difference').
Consistent formatting improves readability and professionalism.
8.
LOWcopyedit
In the Results, Safety section, clarify the sentence listing SAEs to avoid ambiguity about which percentages correspond to which group.
Clearer sentence structure prevents misinterpretation of safety data.
9.
LOWreporting
In the Methods, specify the version of MedDRA used for coding AEs (already mentioned as 27.1, but could be more explicit).
Explicitly stating the MedDRA version enhances methodological transparency.

Full text (58,440 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04103-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/e32281f8-46c9-4a37-8c4c-ffb114eafb82" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/e32281f8-46c9-4a37-8c4c-ffb114eafb82/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 0 high issues for “Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0c49c82270faaa39c97fc72936fbc09e6010f6a132dfa25ff03ce1e8e35ff781

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is the change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) score, which is a functional motor scale, not a hard clinical outcome. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking HFMSE changes to long-term clinical outcomes such as survival or need for ventilation. The claim of clinical benefit is based on a surrogate motor function scale.
“Primary efficacy endpoint was change from baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) score.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect size is a least squares mean difference of 1.88 points on the HFMSE scale (0-66 points), which is a small fraction of the scale range. The paper mentions a 3-point threshold for responder analysis and a 1.5-point minimal clinically important difference, but the observed difference of 1.88 is below the 3-point threshold and only slightly above the 1.5-point MCID. The clinical meaningfulness is not robustly established, especially given the small magnitude relative to the scale.
“least squares mean difference, 1.88 (95% confidence interval: 0.51−3.25); P = 0.0074”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 3 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

“In a completed phase 1/2 dose-ranging trial (STRONG; NCT03381729), OAV101 IT was demonstrated to be safe and well tolerated in patients with SMA aged 6 months to <60 months.”

“As such, there remains a need for a safe and effective, one-time gene therapy option that provides sustained expression of SMN protein.”

Introduction ¶2Find in source

“Challenges associated with chronic administration include the burden of repeated administration and potential non-compliance.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 3]

“In a completed phase 1/2 dose-ranging trial (STRONG; NCT03381729), OAV101 IT was demonstrated to be safe and well tolerated in patients with SMA aged 6 months to <60 months.”

“As such, there remains a need for a safe and effective, one-time gene therapy option that provides sustained expression of SMN protein.”

Introduction ¶2Find in source

“Challenges associated with chronic administration include the burden of repeated administration and potential non-compliance.”

Introduction ¶2Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with randomization, blinding, and a pre-specified analysis plan.

Evidence

MethodsFind in source

“Participants (and their caregivers), clinical evaluators who performed the HFMSE and the RULM assessments and study investigators were blinded.”

MethodsFind in source

“The STEER study aimed to enroll 125 participants to receive OAV101 IT ( n ≈ 75) or sham procedure ( n ≈ 50).”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, and prespecified analysis.

Evidence

MethodsFind in source

“Participants (and their caregivers), clinical evaluators who performed the HFMSE and the RULM assessments and study investigators were blinded.”

MethodsFind in source

“The STEER study aimed to enroll 125 participants to receive OAV101 IT ( n ≈ 75) or sham procedure ( n ≈ 50).”

MethodsFind in source

The paper reports age, sex, SMN2 copy number, and baseline motor function scores. Since both sexes are enrolled, sex justification is not applicable. Age and health status are reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographics and baseline characteristics are well reported, including age, sex, and SMN2 copy number.

Evidence

“Male | 34 (45.3) | 28 (54.9) | 62 (49.2)”

Table 1Find in source

“Mean (s.d.) age at dosing was 5.89 (3.58; range, 2.1–16.6) years for the OAV101 IT group and 5.87 (3.05; range, 2.4–14.2) years for the sham group.”

ResultsFind in source

paraphrase[Table 1]

“SMN2 copy number, n (%) | 2 | 1 (1.3) | 4 (7.8) | 5 (4.0)”

PASSReviewer 2· 90% conf

Demographic and baseline characteristics are well reported, including age, sex, and SMN2 copy number.

Evidence

“Male | 34 (45.3) | 28 (54.9) | 62 (49.2)”

Table 1Find in source

“Mean (s.d.) age at dosing was 5.89 (3.58; range, 2.1–16.6) years for the OAV101 IT group and 5.87 (3.05; range, 2.4–14.2) years for the sham group.”

ResultsFind in source

paraphrase[Table 1]

“SMN2 copy number, n (%) | 2 | 1 (1.3) | 4 (7.8) | 5 (4.0)”

The methods list numerous named IRBs that approved the study, and written informed consent from parents/guardians is stated. Compliance with ICH-GCP and Declaration of Helsinki is declared.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals from named IRBs and informed consent are documented.

Evidence

paraphrase[Methods, Ethics]

“Written informed consent was obtained from parents or legal guardians (and assent as appropriate) before participation.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and informed consent are thoroughly documented.

Evidence

paraphrase[Methods, Ethics]

“Written informed consent was obtained from parents or legal guardians (and assent as appropriate) before participation.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (OAV101 IT) is identified with dose and administration details.

Evidence

“OAV101 IT was delivered as a single IT injection under sedation/anesthesia.”

MethodsFind in source

“evaluating the efficacy and safety of OAV101 IT (1.2 × 10 14 vector genomes)”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product is adequately identified, and statistical software is mentioned.

Evidence

“OAV101 IT delivers the SMN transgene via an AAV9 vector and is identical to that used in the STRONG study and the current intravenous formulation.”

MethodsFind in source

“OAV101 IT (1.2 × 10 14 vector genomes)”

MethodsFind in source

absence[Methods, Data analysis]

Statistical software is not explicitly named.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported.

Evidence

Figure 2Find in source

“least squares mean difference, 1.88 (95% confidence interval: 0.51−3.25); P = 0.0074”

ResultsFind in source

absence[Methods, Data analysis]

Statistical software is not identified.

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals.

Evidence

Figure 2Find in source

paraphrase[Results, Primary efficacy endpoint]

“P = 0.0074”

“least squares mean difference, 1.88 (95% confidence interval: 0.51−3.25)”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement provides a concrete access route via ClinicalStudyDataRequest.

Evidence

paraphrase[Data availability]

“This trial data availability is according to the criteria and process described at https://www.clinicalstudydatarequest.com/.”

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route.

Evidence

Data availabilityFind in source

“This trial data availability is according to the criteria and process described at https://www.clinicalstudydatarequest.com/”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration: ClinicalTrials.gov identifier: NCT05089656”

AbstractFind in source

“Possible limitations of this study include broad inclusion of all patients regardless of baseline HFMSE and wide age range in the eligibility criteria.”

Discussion ¶7Find in source

“Novartis Pharma AG sponsored this clinical trial.”

Competing interestsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with trial registration, limitations, and funding disclosures.

Evidence

“Trial registration: ClinicalTrials.gov identifier: NCT05089656”

AbstractFind in source

“Possible limitations of this study include broad inclusion of all patients regardless of baseline HFMSE and wide age range in the eligibility criteria.”

DiscussionFind in source

“This study was supported by Novartis Pharma AG, which was involved in the study design, data collection, data analysis, data interpretation and writing of all related reports and publications.”

AcknowledgementsFind in source

Registered (3 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 27 references by DOI: 22 verified — 5 no DOI (shown, not verified).

1 data/code link found; not probed for liveness in this run.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
MEDIUMstatistics
In the Methods, Data analysis section, explicitly name the statistical software (e.g., SAS version) used for all analyses.
Naming the software enhances reproducibility and is a standard expectation for clinical trial reporting.
2.
MEDIUMreporting
In the Methods or Reporting Summary, state explicit adherence to CONSORT guidelines and provide the checklist.
Explicitly citing the reporting guideline improves transparency and aligns with journal requirements.
3.
MEDIUMreporting
In the Methods, Data analysis section, specify the software used for the mixed model and logistic regression analyses.
Clarifying the software for specific analyses aids reproducibility.
4.
MEDIUMdata code
In the Data availability section, clarify the timeframe for data access requests.
Providing a timeline helps readers understand when data will be available.
5.
MEDIUMreporting
In the Discussion, add a sentence on the generalizability of the results to broader SMA populations.
Addressing generalizability strengthens the interpretation of the findings.
6.
LOWcopyedit
In the Author list, separate author names with commas and ensure correct formatting (e.g., 'Vũ Dũng Chí Wilmshurst Jo M.').
Correct author formatting is essential for indexing and professional presentation.
7.
LOWcopyedit
In the Abstract, standardize the formatting of confidence intervals (e.g., use en dash consistently) and terminology ('least squares mean difference' vs 'LSM difference').
Consistent formatting improves readability and professionalism.
8.
LOWcopyedit
In the Results, Safety section, clarify the sentence listing SAEs to avoid ambiguity about which percentages correspond to which group.
Clearer sentence structure prevents misinterpretation of safety data.
9.
LOWreporting
In the Methods, specify the version of MedDRA used for coding AEs (already mentioned as 27.1, but could be more explicit).
Explicitly stating the MedDRA version enhances methodological transparency.

Full text (58,440 chars)Analyzed: Aug 15, 2026